Charter Life Sciences





	XLumena Spots $6M For Ultrasound Devices June 4, 2008 Mirabilis Completes First Human Trial of Non-Invasive Treatment for Uterine Fibroids APRIL 28, 2008 Astellas and CoMentis Sign Agreement to Collaborate on the Research, Development and Commercialization of Beta-Secretase Inhibitors APRIL 25, 2008 EnteroMedics Announces Planned Expansion of EMPOWER Pivotal Study for Obesity to 300 Patients February 26, 2008 KFx Medical Corporation Appoints Matt Meyer as its Vice President Marketing February 20, 2008 EnteroMedics(TM) Announces Nine-Month Clinical Results on Its VBLOC-RF2 Feasibility Study for Obesity Therapy January 8, 2008 EnteroMedics(TM) Announces Pivotal Clinical Study of its VBLOC(TM) Therapy for Obesity January 7, 2008 CoMentis Announces Proof-of-Activity-Data from its Phase I Study of Disease-Modifying Alzheimer’s Disease Therapy January 7, 2008 APT Pharmaceuticals Expands Management Team NOVEMBER 19, 2007 EnteroMedics Announces Initial Public Offering NOVEMBER 14, 2007 APT Pharmaceuticals Closes New $22 Million Funding Round OCTOBER 4, 2007 JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial SEPTEMBER 20, 2007 Mirabilis Closes $10.5 Million Series A Extension to Commercialize Non-invasive Treatment of Uterine Fibroids AUGUST 21, 2007 KFx Medical Corporation Closes $10 Million Series B Financing AUGUST 9, 2007 JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial JUNE 18, 2007 CoMentis Announces Appointment of Martin Tolar, M.D., Ph.D., as Vice President JUNE 6, 2007 APT Acquires Exclusive Worldwide Rights to Develop and Commercialize Inhalable Cyclosporine to Prevent Lung Transplant Rejection JUNE 5, 2007 Enteromedics Files Registration Statement for Proposed Initial Public Offering MAY 25, 2007 CoMentis Initiates Phase II Clinical Trial for AMD Eye Drop Therapy APRIL 10, 2007 Athenagen Announces Name Change to CoMentis FEBRUARY 10, 2007 Athenagen’s Eye Drop Therapy for AMD is Safe and Well Tolerated in Phase I Study JANUARY 31, 2007 Athenagen Initiates Phase II Clinical Trial in Alzheimer’s Disease DECEMBER 13, 2006 Mirabilis Medica Names Mike Connolly CEO OCTOBER 3, 2006 Athenagen Raises $50 Million in Series B Financing SEPTEMBER 28, 2006 Amaranth Medical Closes $7.5 Million Series A Financing to Advance the Development of Bio-Absorbable Stents SEPTEMBER 26, 2006 Mirabilis Raises $4 Million to Commercialize Non-Invasive Treatment of Uterine Fibroids AUGUST 29, 2006 Athenagen Initiates Clinical Development of its Anti-angiogenic Eye Drop Therapy for AMD AUGUST 21, 2006 Athenagen Completes Merger with Zapaq AUGUST 14, 2006 KFx Medical Corporation Receives 510k Clearance for Knotless Tissue Fixation AUGUST 10, 2006 Athenagen Announces Publication of Results from a Proof-of-Concept Trial of its Novel alpha-7 Nicontinic Receptor Agonist in Schizophrenia JUNE 15, 2006 Athenagen Acquires Osprey Pharmaceutical Company - Adds Clinical-Stage Alzheimer's Drug Candidate to its Pipeline APRIL 13, 2006 Aradigm and APT Pharmaceuticals Initiate Phase 2 Clinical Program of Novel Treatment for Asthma MARCH 23, 2006 Athenagen Adds A. Barr Dolan to its Board of Directors FEBRUARY 22, 2006 Previous News Stories >


	KFx Medical Corporation Closes $10 Million Series B Financing SAN DIEGO, CA – AUGUST 9, 2007 KFx Medical Corporation, a developer of minimally invasive percutaneous repair systems for rotator cuff repair, has closed a Series B financing. Investors in the $10M Series B round included lead investor Alloy Ventures and returning investors Charter Life Sciences L.P, Arboretum Ventures, Montreux Equity Partners, and MB Venture Partners. "The participation of Alloy Ventures and its partner Craig Taylor, along with the return of our previous investors is very rewarding," stated KFx president and CEO Tate Scott. "This financing enables us to further our goals as we begin the distribution of the most secure rotator cuff repair available." Joining the KFx Board of directors is Craig C. Taylor, Managing Partner of Alloy. He joins Scott and former Vivant Medical CEO Rod Young, Barr Dolan of Charter, Tim Petersen of Arboretum and Dr. John Savarese of Montreux. MB Venture Partners Stephen Snowdy is a board observer. Over four million people seek medical advice for shoulder pain every year; torn rotator cuffs alone account for more than 500,000 surgeries annually and have traditionally required many weeks of rehabilitation. Patients typically experience less pain and regain full range of motion more quickly with traditional minimally invasive techniques however these require surgeons to have advanced videoscopic skills. In contrast, KFx provides a simple system for surgeons which ensures a more anatomical repair and yields a better clinical outcome for the patient. "We have followed the progress of KFx in development and in the clinic and are pleased to assist in expanding the use of this advanced system," Taylor stated. About KFx Medical Corporation Headquartered in Carlsbad, Calif., KFx Medical Corporation was founded in 2003 to develop clinically relevant solutions to rotator cuff repair. The company is privately held. For more information: www.KFxmed.com CONTACT: Tate Scott KFx Medical Corporation 5145 Avenida Encinas, Ste C Carlsbad, CA 92008 619 270-8474